(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 June 2022 (09.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/119974 A1

(51) International Patent Classification:
*A61K 38/46* (2006.01) *A61P 21/00* (2006.01)

(21) International Application Number:
PCT/US2021/061482

(22) International Filing Date:
01 December 2021 (01.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/119,977 01 December 2020 (01.12.2020) US
63/130,060 23 December 2020 (23.12.2020) US

(71) Applicant: **LOCANABIO, INC.** [US/US]; 3545 John Hopkins Court, Suite 200, San Diego, California 92121 (US).

(72) Inventors: **NELLES, David A.**; c/o Locanabio, Inc., 3545 John Hopkins Court, Suite 200, San Diego, California 92121 (US). **BATRA, Ranjan**; c/o Locanabio, Inc., 3545 John Hopkins Court, Suite 200, San Diego, California 92121 (US). **ROTH, Daniela**; c/o Locanabio, Inc., 3545 John Hopkins Court, Suite 200, San Diego, California 92121 (US). **ZISOULIS, Dimitrios**; c/o Locanabio, Inc., 3545 John Hopkins Court, Suite 200, San Diego, California 92121 (US). **TA, Angeline**; c/o Locanabio, Inc., 3545 John Hopkins Court, Suite 200, San Diego, California 92121 (US).

(74) Agent: **ELRIFI, Ivor** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING CAG REPEAT DISEASES





FIG. 3C

(57) Abstract: Disclosed are RNA-targeting gene therapy compositions and methods for destroying or blocking toxic target CAG repeat RNA and treating CAG repeat disorders such as Huntington's Disease (HD) and Spinocerebellar Ataxia Type 1 (SCA1).

WO 2022/119974 A1